Celgene pays Dragonfly $50M to expand NK cell immunotherapy deal

Celgene Corp. (NASDAQ:CELG) expanded its deal with Dragonfly Therapeutics Inc. (Waltham, Mass.), doubling the number of trispecific NK cell engager cancer compounds that Celgene may in-license.

Under the expansion, Celgene will pay Dragonfly $50 million up front for an option to license exclusive, worldwide rights to products developed using the biotech's TriNKET platform against four undisclosed solid and hematological tumor targets. Dragonfly is eligible to receive undisclosed milestones and royalties...